Gilead Sciences (NasdaqGS:GILD) Advances HIV Treatment With Promising Lenacapavir And Biktarvy Data [Yahoo! Finance]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Yahoo! Finance
This upward trajectory coincides with positive developments in its HIV treatment portfolio, highlighted by successful data presentations at CROI 2025. The approval of lenacapavir for multi-drug resistant HIV and its promising trial results for once-yearly PrEP injections in significant publications emphasized Gilead's innovative edge. Coupled with robust earnings in Q4 2024, where revenue and net income grew from the previous year, and a positive outlook for 2025 sales excluding Veklury, investor confidence appears bolstered. Additionally, the general market saw a modest recovery with Nasdaq appreciating, although tech stocks were more positively impacted. The 2.6% dividend increase also suggests strong financial health, likely enhancing Gilead's attractiveness to investors. Overall, these events seem to have positively influenced Gilead's stock performance amid broader market volatility. Explore the potential challenges for Gilead Sciences in our thorough risk analysis report. Na
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Update: Gilead Sciences to Acquire Repare Therapeutics' Investigational Cancer Treatment; Repare Shares Rise [Yahoo! Finance]Yahoo! Finance
- Repare Therapeutics Announces Acquisition of Pol? ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences to Present at Upcoming Investor ConferenceBusiness Wire
- Biopharma climbs higher as 9 drugmakers ink ‘pandering' drug price deals with Trump [Yahoo! Finance]Yahoo! Finance
- 3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026 [Yahoo! Finance]Yahoo! Finance
GILD
Earnings
- 10/30/25 - Beat
GILD
Sec Filings
- 12/16/25 - Form 4
- 12/16/25 - Form 4
- 12/15/25 - Form 144
- GILD's page on the SEC website